Skip to main content


Recent Development in Cancer Immunotherapy

Edited by Prof Weijing Sun

Due to recent technological and scientific advancements, the past few years have seen dramatic breakthroughs in the burgeoning field of immunotherapy. These and future advances in immunotherapy have the potential to transform cancer treatment and the lives of patients.

This thematic series, published in the Journal of Hematology & Oncology, covers some of the recent advances in cancer immunotherapy.

As discussed by Prof Weijing Sun in the Editorial, important issues addressed by the authors in this series include: the identification of clinically relevant predictive and prognostic biomarkers to help define subgroups of patients who are most likely to benefit from various immunotherapies; management of immunotherapy-related toxicities and resistance; and future directions and approaches.

  1. Review

    Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia

    Currently, conventional therapies for acute myeloid leukemia (AML) have high failure and relapse rates. Thus, developing new strategies is crucial for improving the treatment of AML. With the clinical success ...

    Mingxue Fan, Minghao Li, Lipeng Gao, Sicong Geng, Jing Wang, Yiting Wang, Zhiqiang Yan and Lei Yu

    Journal of Hematology & Oncology 2017 10:151

    Published on: 29 August 2017

  2. Review

    Recent developments in immunotherapy of acute myeloid leukemia

    The advent of new immunotherapeutic agents in clinical practice has revolutionized cancer treatment in the past decade, both in oncology and hematology. The transfer of the immunotherapeutic concepts to the tr...

    Felix S. Lichtenegger, Christina Krupka, Sascha Haubner, Thomas Köhnke and Marion Subklewe

    Journal of Hematology & Oncology 2017 10:142

    Published on: 25 July 2017

  3. Review

    The next generation of immunotherapy: keeping lung cancer in check

    Lung cancer is the deadliest malignancy with more cancer deaths per year than the next three cancers combined. Despite remarkable advances in targeted therapy, advanced lung cancer patients have not experience...

    Ashwin Somasundaram and Timothy F. Burns

    Journal of Hematology & Oncology 2017 10:87

    Published on: 24 April 2017

  4. Review

    Immunotherapy in hematologic malignancies: past, present, and future

    The field of immunotherapy in cancer treatments has been accelerating over recent years and has entered the forefront as a leading area of ongoing research and promising therapies that have changed the treatme...

    Annie Im and Steven Z. Pavletic

    Journal of Hematology & Oncology 2017 10:94

    Published on: 24 April 2017

  5. Review

    The use of immunotherapy in the treatment of melanoma

    Patients with advanced melanoma have a compromised anti-tumor immune response leading to tumor immune tolerance and a tumor microenvironment conducive to disease progression. Immunotherapy that successfully ov...

    Tala Achkar and Ahmad A. Tarhini

    Journal of Hematology & Oncology 2017 10:88

    Published on: 24 April 2017

  6. Review

    Immunotherapy in genitourinary malignancies

    Treatment of cancer patients involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. Traditionally, patients with metastatic disease are treated with combination chemotherapies...

    Kathan Mehta, Keyur Patel and Rahul A. Parikh

    Journal of Hematology & Oncology 2017 10:95

    Published on: 24 April 2017

  7. Review

    Chimeric antigen receptor T cells: a novel therapy for solid tumors

    The chimeric antigen receptor T (CAR-T) cell therapy is a newly developed adoptive antitumor treatment. Theoretically, CAR-T cells can specifically localize and eliminate tumor cells by interacting with the tu...

    Shengnan Yu, Anping Li, Qian Liu, Tengfei Li, Xun Yuan, Xinwei Han and Kongming Wu

    Journal of Hematology & Oncology 2017 10:78

    Published on: 29 March 2017